0001551306-26-000068
SEC filingProfitability strengthened significantly with operating income up 46.4% to $35.4M and net income rising 60.9% to $24.2M, driven by care management efficiencies, lower stock-based compensation, and disciplined expense management despite modest 1.4% revenue growth.
Progyny delivered strong profitability growth in Q1 FY2026, with revenue of $328.5 million up 1.4% from $324.0 million in the prior year quarter. This modest top-line increase reflects the company's ability to expand its platform addressing the women's health continuum—from fertility benefits launched in 2016 to solutions in pregnancy, postpartum, menopause, and parent wellbeing—while prescription drugs are dispensed through contracted mail order specialty pharmacies and supported by formulary management and care services.
Gross profit improved to $83.1 million, a 9.6% increase, expanding gross margin to 25.3%. As noted in management discussion, this reflects ongoing efficiencies in delivering care management services alongside a decrease in stock-based compensation expense. These improvements underscore the scalability of Progyny's model as it serves employer clients, with staffing and related costs expected to grow alongside client additions but offset by operational leverage.